Longeveron Inc. - Class A Common stock (LGVN)

ELPIS II trial data expected September 2026 as cash runway extends into Q4.

Longeveron (LGVN) Q1 2026 Earnings Transcript

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.